Follow The Filings

AEON AEON Biopharma

AEON Biopharma earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by AEON's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AEON insider trades
  • $243K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Timothy P Lynch 10% owner
    Buy
    $243K 1,150,000 shares at $0.2100 +22% to stake
    Traded Aug 19 Filed Aug 21

Also filed in the last 12 months, not counted as buying or selling: 13 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,9.01
8-K 7.01,8.01,9.01
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q
8-K 7.01,8.01,9.01
8-K 8.01
SCHEDULE 13G —
424B4
8-K 1.01,8.01,9.01
S-1/A
S-1
8-K 5.07
8-K 2.02,9.01
10-Q
8-K 7.01,9.01
DEF 14A
DEFA14A
8-K 3.01,9.01
8-K 2.02,9.01
10-K
8-K 5.02,9.01
424B3
SCHEDULE 13D/A —
SCHEDULE 13D —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.